PI-88 and novel heparan sulfate mimetics inhibit angiogenesis

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 5, 2007, Pages 557-562

  Ferro, Vito ^a   Dredge, Keith ^a   Liu, Ligong ^a   Hammond, Edward ^a   Bytheway, Ian ^a   Li, Caiping ^a   Johnstone, Ken ^a   Karoli, Tomislav ^a   Davis, Kat ^a   Copeman, Elizabeth ^a   Gautam, Anand ^a  

^a Progen Pharmaceuticals Ltd   (Australia)

Author keywords

Angiogenesis inhibitors; Heparan sulfate mimetics; Heparanase inhibitors; PI 88; Sulfated oligosaccharides

Indexed keywords

ANGIOGENESIS INHIBITOR; DACARBAZINE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE; HEPARANASE; MATRIGEL; MAZATICOL; OLIGOSACCHARIDE; PG 500; PG 517; PG 518; PG 522; PG 524; PI 88; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER INHIBITION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; THROMBOCYTOPENIA;

ANIMALS; BIOMIMETIC MATERIALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; HEPARIN LYASE; HEPARITIN SULFATE; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOSACCHARIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547092688     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-982088     Document Type: Conference Paper

References (28)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410
3. Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 2006;11: 635-650
4. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-528
5. Wegrowski Y, Maquart FX. Involvement of stromal proteoglycans in tumour progression. Crit Rev Oncol Hematol 2004; 49:259-268
6. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-148
7. Presta M, Leali D, Stabile H, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003;9:553-566
8. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59: 3433-3441
9. Cochran S, Li C, Fairweather JK, et al. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem 2003;46:4601-4608
10. Khachigian LM, Parish CR. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev 2004; 22:1-6
11. Hazel SJ. A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances. J Lab Clin Med 2003;141:217-228
12. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005;24:4037-4051 [Corrigenda in Oncogene 2005;24:4163]
13. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018-2039
14. Hammond E, Bytheway I, Ferro V. Heparanase as a target for anticancer therapeutics: new developments and future prospects. In: Delehedde M, Lortat-Jacob H, eds. New Developments in Therapeutic Glycomics. Kerala, India: Research Signpost; 2006:251-282
15. Demir M, Iqbal O, Hoppensteadt DA, et al. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thromb Hemost 2001;7:131-140
16. Yu G, Gunay NS, Linhardt RJ, et al. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur J Med Chem 2002;37:783-791
17. Ferro V, Fewings K, Palermo MC, Li C. Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88. Carbohydr Res 2001;332:183-189
18. Ferro V, Li C, Fewings K, et al. Determination of the composition of the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y-2448 phosphomannan by capillary electrophoresis and HPLC. Carbohydr Res 2002; 337:139-146
19. Iversen PO, Sorensen DR, Benestad HB. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. Leukemia 2002;16:376-381
20. Rosenthal MA, Rischin D, McArthur G, et al. Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol 2002;13: 770-776
21. Basche M, Gustafson DL, Holden SN, et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006;12:5471-5480
22. Gautam AM, Ferro V, Wilson EA, Freeman C, Parish C. PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials. Paper presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. November 14-18, 2005; Philadelphia, PA
23. Chen P, Chang S, Lai C, Gautam A, Wilson E. Use of PI-88, a novel heparanase inhibitor, as adjuvant therapy in post-resection hepatocellular carcinoma: a large randomised phase II clinical trial. Paper presented at: Shanghai-Hong Kong International Liver Congress. March 25-28, 2006; Shanghai, China
24. Poon RT, Fan ST, Lo CM, et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000;18:1094-1101
25. Karoli T, Liu L, Fairweather JK, et al. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J Med Chem 2005;48:8229-8236
26. Nyberg K, Ekblad M, Bergstrom T, et al. The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus. Antiviral Res 2004;63:15-24
27. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60: 2178-2189
28. McCarty MF, Baker CH, Bucana CD, Fidler IJ. Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 2002;21:5-10